Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 4/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13751143 | 0.95 | SMN1; SMN2 (0.41) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL19117547 | 0.91 | HTR7 (0.41) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL17545829 | 0.91 | HTR7 (0.37) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL8369139 | 0.91 | HTR7 (0.41) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL13848547 | 0.91 | HTR7 (0.41) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL13848576 | 0.91 | HTR7 (0.41) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL17547032 | 0.91 | HTR7 (0.41) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL22302351 | 0.90 | SMN1; SMN2 (0.39) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL13179113 | 0.89 | GNAI3 (0.34) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 | |
| SCHEMBL22819552 | 0.87 | SMN1; SMN2 (0.48) | GNAI3GNAO1GNAI1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066371-A1 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-20210147445-A1 | HETEROCYCLIC COMPOUND AS TRK INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| WO-2008066874-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147445-A1 | HETEROCYCLIC COMPOUND AS TRK INHIBITOR | NADK, NTRK3, TNNI3K | GNAI3 586/4885GNAO1 1125/4885GNAI1 511/4885 |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | CSNK1G3, CSNK1A1, CSNK1A1L | GNAI3 529/4885GNAO1 642/4885GNAI1 760/4885 |
| US-20120184543-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | PLK2, PLK3, DMPK | GNAI3 1575/4885GNAO1 2963/4885GNAI1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.